1
Peter Bacher, Jeanine M Walenga: Catheter and method for the prevention and/or treatment of stenotic processes of vessels and cavities. Loyola University of Chicago, Marshall O Toole Gerstein Murray & Borun, February 4, 1997: US05599307 (159 worldwide citation)

A catheter for preventing the stenosis or restenosis of a body vessel or cavity, e.g., a blood vessel, whereby a membrane may be applied to the inner surface of the vessel or cavity. The inventive catheter tip utilizes (a) two inflatable chamber balloons which, when inflated, isolate a portion of th ...


2
Willson H Burgess, Howard P Greisler, William N Drohan, Thomas Maciag, Martin J MacPhee: Method of preparing a tissue sealant-treated biomedical material. Loyola University of Chicago, The American National Red Cross, Sterne Kessler Goldstein & Fox P L L C, May 6, 2003: US06559119 (84 worldwide citation)

This invention provides methods for the preparation of a tissue sealant-treated biomaterial, wherein the tissue sealant used in the method comprises at least one composition which is selected from one or more antibodies, analgesics, anticoagulants, anti-inflammatory compounds, antimicrobial composit ...


3
Katherine L Knight: Immortalized rabbit hybridoma fusion partner. Loyola University of Chicago, Leydig Voit & Mayer, October 7, 1997: US05675063 (44 worldwide citation)

Novel methods are provided for producing rabbit fusion partners for the production of specific binding proteins, particularly immunoglobulins. Nuclei of rabbit fertilized ova are microinjected with an oncogene to express specifically in lymphoid cells (i.e., lymphoid specific) and the embryos are th ...


4
Wayne R Hanson: Protective prostaglandins for use in conjunction with chemotherapeutic agents. Loyola University of Chicago, Cynthia S Kovacevic, Roger A Williams, November 26, 1996: US05578643 (40 worldwide citation)

Prostaglandins of the PGE type can be administered in a therapeutically effective amount to protect tissue from injury resulting from chemotherapeutic agents by administering the PGE-type prostaglandin prior to administration of the chemotherapeutic agent.


5
Ioannis Scarpa, Anita Beavins: Cellulose chromatography support. Loyola University of Chicago, Marshall O Toole Gerstein Murray & Borun, September 14, 1993: US05245024 (39 worldwide citation)

This invention relates to an improved cellulose chromatography support and, in particular, to substantially spherical, high density cellulose particles. This invention also relates to a method of making these spherical, high density cellulose particles and, in particular, to a method for forming sph ...


6
Wayne R Hanson: Protective prostaglandins for use in conjunction with chemotherapeutic agents. Loyola University of Chicago, Cynthia S Kovacevic, Roger A Williams, February 25, 1997: US05605931 (33 worldwide citation)

Prostaglandins of the PGE type can be administered in a therapeutically effective amount to protect tissue from injury resulting from chemotherapeutic agents by administering the PGE-type prostaglandin prior to administration of the chemotherapeutic agent.


7
Lutz Gissmann, Martin Müller: Papilloma virus capsomere formulations and method of use. Loyola University of Chicago, Marshall O&apos Toole Gerstein Murray & Borun, May 8, 2001: US06228368 (26 worldwide citation)

Vaccine formulations comprising viral capsomeres are disclosed along with methods for their production. Therapeutic and prophylactic methods of use for the vaccine formulations are also disclosed.


8
Wayne R Hanson: Protective prostaglandins for use in conjunction with chemotherapeutic agents. Loyola University of Chicago, Cynthia S Kovacevic, Roger A Williams, November 26, 1996: US05578640 (25 worldwide citation)

Prostaglandins of the PGE type can be administered in a therapeutically effective amount to protect tissue from injury resulting from chemotherapeutic agents by administering the PGE-type prostaglandin prior to administration of the chemotherapeutic agent.


9
Lutz Gissmann, Jian Zhou, Martin Muller, Jeanette Painstil: Carboxyl terminal of papilloma virus L1 region is not required for formation of virus-like particles. Loyola University of Chicago, Marshall O Toole Gerstein Murray & Borun, May 23, 2000: US06066324 (19 worldwide citation)

Recombinant papilloma virus-like particles result from the expression of viral structural protein L1 and/or L2 in which one or several sections of the L1 and/or L2 protein are deleted. The ability to form virus-like particles is at least the same as, preferably higher than, that of native reproducti ...


10
Mary K Boyd, G Robert Goss: Silane-modified clay. Loyola University of Chicago, Olson & Hierl, October 20, 1998: US05824226 (18 worldwide citation)

Clay particles with organo silane-modified surfaces are provided along with a process for their preparation. The silane-modified clay is relatively easily and reliably produced by reacting clay with a R-substituted halosilane (R being a hydrophobic group) in a polar solvent containing a tertiary ami ...